Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OFIRMEV vs AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.
Amiloride is a potassium-sparing diuretic that blocks epithelial sodium channels (ENa C) in the distal convoluted tubule and collecting duct, inhibiting sodium reabsorption and reducing potassium excretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, increasing sodium, chloride, and water excretion.
Management of mild to moderate pain,Management of moderate to severe pain with adjunctive opioid analgesics,Reduction of fever
Hypertension,Edema associated with congestive heart failure, cirrhosis, or nephrotic syndrome,Hypokalemia prevention or correction in patients on diuretics
IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.
One tablet (amiloride 5 mg/hydrochlorothiazide 50 mg) orally once daily initially, increased if needed to twice daily. Maximum dose: amiloride 10 mg/hydrochlorothiazide 100 mg daily.
Terminal elimination half-life is 2-3 hours in adults (2.5-3 hours in children). Clinically, dosing every 4-6 hours is needed to maintain therapeutic levels.
Amiloride: 6-9 hours (prolonged in renal impairment); Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment, heart failure).
Acetaminophen is primarily metabolized in the liver via conjugation with glucuronide (50-60%) and sulfate (20-30%). A minor amount is oxidized by cytochrome P450 (CYP2E1, CYP1A2, CYP3A4) to a toxic reactive metabolite (NAPQI), which is normally detoxified by glutathione. At toxic doses, glutathione is depleted, leading to NAPQI accumulation and hepatotoxicity.
Amiloride is not metabolized; excreted unchanged in urine. Hydrochlorothiazide is not extensively metabolized; small amounts are metabolized hepatically via CYP450 enzymes, but the exact pathways are not well defined.
Primarily renal (85% as sulfate and glucuronide conjugates, 10% as unchanged drug). Less than 5% fecal/biliary.
Amiloride: 50% unchanged in urine, 40% in feces (biliary); Hydrochlorothiazide: >95% unchanged in urine.
10-25% bound to albumin at therapeutic concentrations.
Amiloride: ~23%; Hydrochlorothiazide: 40-68% (primarily to albumin).
0.8-1.0 L/kg. Indicates distribution into total body water.
Amiloride: 350-440 L (5-6 L/kg in 70 kg adult), indicating extensive tissue distribution; Hydrochlorothiazide: 3-5 L/kg, distributes into extracellular space.
100% (intravenous); not applicable for other routes as OFIRMEV is IV only.
Amiloride: 50-80% (oral); Hydrochlorothiazide: 60-80% (oral).
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, extend dosing interval to every 8 hours; maximum daily dose 3000 mg.
Contraindicated if GFR <30 m L/min or serum creatinine >2.5 mg/d L. For GFR 30-50 m L/min: use with caution and monitor electrolytes; avoid if further renal impairment.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce total daily dose by 50% (max 2000 mg/day). Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose to 50% of standard and extend interval to every 8 hours; maximum 2000 mg/day.
Child-Pugh Class A: no adjustment; Class B: reduce dose or use alternative; Class C: avoid use (risk of hepatic encephalopathy).
Weight-based: <10 kg: 7.5 mg/kg/dose every 6 hours; 10-50 kg: 15 mg/kg/dose every 6 hours; >50 kg: 1000 mg every 6 hours or 650 mg every 4 hours. Maximum single dose: 15 mg/kg (up to 1000 mg); maximum daily dose: 75 mg/kg (up to 4000 mg).
Not established; safety and efficacy not determined in children.
No specific dose adjustment; consider reduced renal function. For Cr Cl <30 m L/min, extend interval to every 8 hours. Maximum daily dose: 3000 mg in frail elderly or with comorbidities.
Start at lowest dose, monitor electrolytes and renal function; increased sensitivity to hypotension and electrolyte disturbances; avoid if creatinine clearance <30 m L/min.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
None
Risk of serious hepatotoxicity, especially with doses >4000 mg/day or in patients with underlying liver disease,Risk of severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis) – discontinue at first sign of rash,Risk of hypersensitivity reactions including anaphylaxis,Use caution in patients with severe hepatic impairment, active hepatic disease, or alcoholism,Avoid concurrent use of other acetaminophen-containing products
Hyperkalemia risk, especially with renal impairment, diabetes, or concomitant use of potassium supplements, ACE inhibitors, or aldosterone antagonists,Electrolyte imbalances (hyponatremia, hypomagnesemia, hypochloremia),Azotemia and renal impairment,Sulfonamide hypersensitivity cross-reactivity (hydrochlorothiazide is a sulfonamide derivative),Acute angle-closure glaucoma (rare with thiazides),Monitor serum electrolytes, renal function, and blood glucose
Known hypersensitivity to acetaminophen or any component of the formulation,Severe hepatic impairment or active liver disease (relative contraindication without black box)
Anuria,Acute or chronic renal insufficiency (creatinine clearance <10 m L/min),Hyperkalemia (serum potassium >5.5 m Eq/L),Concomitant use of other potassium-sparing diuretics, potassium supplements, or amiloride-containing drugs,Hypersensitivity to amiloride, hydrochlorothiazide, or sulfonamide-derived drugs
No known food interactions. However, avoid excessive alcohol consumption as it may increase the risk of liver damage.
Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes) in large amounts. Limit salt intake. Grapefruit juice may increase hydrochlorothiazide absorption; avoid concurrent consumption.
Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dose use in third trimester may be associated with preterm birth or low birth weight. Avoid prolonged use above recommended doses.
First trimester: Limited data; thiazide use associated with possible increased risk of congenital anomalies including neural tube defects and limb reduction defects, but evidence is inconclusive. Second and third trimesters: Hydrochlorothiazide may cause fetal/neonatal electrolyte disturbances, jaundice, and thrombocytopenia. Amiloride has not been associated with major teratogenic effects in animal studies, but human data are inadequate. Overall risk is moderate; avoid in pregnancy if possible, especially for treatment of hypertension, as alternatives exist.
Acetaminophen is excreted in breast milk in low concentrations (M/P ratio approximately 0.9-1.0). Considered compatible with breastfeeding; peak milk levels occur 1-2 hours after maternal dosing. Use lowest effective dose for shortest duration.
Hydrochlorothiazide is excreted into breast milk in low amounts (M/P ratio approximately 1.5); amiloride is also excreted in animal milk but human data lacking. Potential for neonatal electrolyte imbalance and thrombocytopenia from thiazide. Use during breastfeeding is not recommended unless essential. Monitor infant for signs of dehydration and electrolyte disturbances.
No dose adjustment required during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may lead to lower peak concentrations but standard dosing remains effective. Maximum single dose: 1 g; maximum daily dose: 4 g.
No specific dose adjustments recommended for pregnancy due to lack of pharmacokinetic studies; however, increased renal clearance during pregnancy may reduce diuretic efficacy. Caution with hypovolemia and electrolyte disturbances. Use lowest effective dose and consider alternative agents for hypertension in pregnancy (e.g., methyldopa, labetalol).
OFIRMEV (acetaminophen) injection is an IV formulation of acetaminophen used for pain and fever management. It is a prodrug that requires no hepatic conversion, providing rapid onset of action. Monitor for hepatotoxicity; maximum daily dose is 4 grams in adults but lower in patients with hepatic impairment or malnutrition. Do not exceed 1 gram per dose. Hypotension and anaphylaxis have been reported. Not interchangeable with oral acetaminophen due to dose equivalency. Use with caution in patients with alcohol use disorder.
Amiloride is potassium-sparing; hydrochlorothiazide causes potassium loss. The combination offsets hypokalemia risk. Monitor serum potassium, especially in renal impairment or with NSAIDs. Avoid in anuria or severe renal disease. Onset of diuresis: 2 hours; peak effect: 6-12 hours; duration: 24 hours.
OFIRMEV is given intravenously for pain or fever.,Do not take additional acetaminophen-containing medications while receiving OFIRMEV.,Report any signs of allergic reaction (rash, itching, swelling, trouble breathing).,Seek immediate medical attention if you experience severe abdominal pain, yellowing of skin or eyes, or dark urine.,Inform your healthcare provider about all medications you are taking, especially blood thinners.
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,This drug increases urine output and may cause dizziness or lightheadedness; rise slowly from sitting or lying down.,Avoid potassium supplements or salt substitutes containing potassium unless directed by your doctor.,Limit alcohol intake as it can increase dizziness and orthostatic hypotension.,Notify your doctor if you experience muscle cramps, weakness, irregular heartbeat, or excessive thirst.
No interactions on record
"The coadministration of Sulindac, a nonsteroidal anti-inflammatory drug (NSAID), with Chlorothiazide, a thiazide diuretic, may result in a diminished antihypertensive and diuretic effect of Chlorothiazide. Sulindac can inhibit renal prostaglandin synthesis, leading to sodium and water retention, which counteracts the natriuretic and hypotensive actions of Chlorothiazide. This interaction may result in reduced blood pressure control and potentially exacerbate edema in patients with hypertension or heart failure."
"Concomitant use of torasemide, a loop diuretic, and chlorothiazide, a thiazide diuretic, produces synergistic blockade of sodium reabsorption along the nephron, leading to profound diuresis, electrolyte disturbances, and volume depletion. This combination increases the risk of severe hypokalemia, hyponatremia, hypomagnesemia, and metabolic alkalosis, potentially precipitating cardiac arrhythmias, hypotension, or renal impairment, especially in patients with compromised renal function or those on digoxin or antiarrhythmics."
"Flurandrenolide, a topical corticosteroid, can be absorbed systemically and enhance the hypokalemic effect of chlorothiazide, a thiazide diuretic. This interaction occurs through additive potassium-wasting actions: flurandrenolide promotes renal potassium excretion via mineralocorticoid-like effects, while chlorothiazide increases distal tubular potassium loss. Clinically, this can lead to severe hypokalemia, potentially causing cardiac arrhythmias, muscle weakness, and impaired glucose tolerance."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OFIRMEV vs AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, answered by our medical review team.
OFIRMEV is a Non-opioid Analgesic that works by OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.. AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE is a Thiazide Diuretic that works by Amiloride is a potassium-sparing diuretic that blocks epithelial sodium channels (ENa C) in the distal convoluted tubule and collecting duct, inhibiting sodium reabsorption and reducing potassium excretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, increasing sodium, chloride, and water excretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OFIRMEV and AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OFIRMEV is: IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.. The standard adult dose of AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE is: One tablet (amiloride 5 mg/hydrochlorothiazide 50 mg) orally once daily initially, increased if needed to twice daily. Maximum dose: amiloride 10 mg/hydrochlorothiazide 100 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OFIRMEV and AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OFIRMEV is classified as Category C. Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dos. AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE is classified as Category A/B. First trimester: Limited data; thiazide use associated with possible increased risk of congenital anomalies including neural tube defects and limb reduction defects, but evidence i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.